First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks climbs on ‘impressive’ celiac study data

Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential.

First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks Biotherapeutics (NASDAQ:TRAX) reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic and symptom-related objectives during a placebo-controlled gluten challenge. The cohort enrolled 3

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage

New drug may offer treatment for coeliac disease

First Tracks Biotherapeutics’ experimental treatment reduced symptoms and helped prevent gut damage after gluten exposure.

First Tracks Biotherapeutics Releases Initial Study Data on CD122-Targeting Drug for Celiac Disease

First Tracks Biotherapeutics released initial study data on Monday regarding a new drug candidate designed to target the CD122 protein for the treatment of celiac disease. Analysts noted that the findings suggest the drug may possess the potential to treat multiple conditions, a concept often referred to as a “pipeline-in-a-product.” The study focuses on the drug’s interaction with the CD122 protein, a biological target that plays a role in immu…